Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rademikibart - Suzhou Connect Biopharmaceuticals

Next Previous
Drug Profile

Rademikibart - Suzhou Connect Biopharmaceuticals

Alternative Names: CBP 201

Latest Information Update: 14 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Suzhou Connect Biopharmaceuticals
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 4 receptor alpha subunit antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Asthma; Atopic dermatitis

Highest Development Phases

  • Phase II Asthma; Atopic dermatitis; Rhinosinusitis
  • No development reported Nasal polyps

Most Recent Events

  • 12 Dec 2023 Connect Biopharma Holdings plans to schedule an End of phase II (EoP2) meeting with the US FDA to discuss Rademikibart’s phase III regulatory path
  • 12 Dec 2023 Efficacy and safety data from a phase II trial in Asthma released by Connect Biopharma Australia
  • 12 Dec 2023 Connect Biopharmaceuticals plans a phase III trial for Asthma
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top